In the ear, IGF1 is currently being studied as a potential polypeptide to be used in the treatment of sensorineural hearing loss and the first results of a clinical trial involving 25 patients with sudden sensorineural hearing loss are very promising (Nakagawa et al., 2014; Yamamoto et al., 2014). Here, IGF1 is linked to hearing loss disorder.